# EDGAR Filing Document

**Accession Number:** 0001730430
**File Stem:** 0001104659-26-019184
**Filing Date:** 2026-2
**Character Count:** 42851
**Document Hash:** 124405e0882dc9afd840348b97f656de
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-019184.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001104659-26-019184

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260224

**DATE AS OF CHANGE**: 20260224

**EFFECTIVENESS DATE**: 20260224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kiniksa Pharmaceuticals International, plc
- **CENTRAL INDEX KEY:** 0001730430
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981795578
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293695
- **FILM NUMBER:** 26672531

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 105 PICCADILLY, SECOND FLOOR
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** W1J 7NJ
- **BUSINESS PHONE:** 7814319100

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 105 PICCADILLY, SECOND FLOOR
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** W1J 7NJ

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kiniksa Pharmaceuticals, Ltd.
- **DATE OF NAME CHANGE:** 20180205

**As filed with the Securities and Exchange Commission on February 24, 2026**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Kiniksa Pharmaceuticals International, plc**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **England and Wales** | **98-1795578** |
| (State or other jurisdiction of incorporation or<br> organization) | (I.R.S. Employer Identification No.) |

---

**Kiniksa Pharmaceuticals International, plc**

**105 Piccadilly, Second Floor**

**London, W1J 7NJ**

**England, United Kingdom**

**(781) 431-9100**

(Address of Principal Executive Offices) (Zip Code)

**Kiniksa Pharmaceuticals International, plc 2018 Incentive Award Plan<br> Kiniksa Pharmaceuticals International, plc 2018 Employee Share Purchase Plan**

(Full title of the plan)

**Kiniksa Pharmaceuticals Corp.**

**100 Hayden Avenue**

**Lexington, MA 02421**

(Name and address for agent for service)

**(781) 431-9100**

(Telephone number, including area code, of agent for service)

**Copies to:**

**Paul M. Kinsella**

**Marko S. Zatylny**

**Ropes & Gray LLP**

**Prudential Tower**

**800 Boylston Street**

**Boston, Massachusetts 02199**

**(617) 951-7000**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ⌧ Accelerated filer ◻ <br> Non-accelerated filer ◻ Smaller reporting company ◻ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**PART I**

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 3,051,742 Class A ordinary shares, nominal value $0.000273235 per share ("Class A ordinary shares") of Kiniksa Pharmaceuticals International, plc (the "Registrant") to be issued pursuant to the Registrant's 2018 Incentive Award Plan (the "2018 Plan") and an additional 110,000 Class A ordinary shares of the Registrant to be issued pursuant to the Registrant's 2018 Employee Share Purchase Plan (the "2018 ESPP"). Registration Statements of the Registrant on Forms S-8 relating to the same employee benefit plans are effective.

**INCORPORATION BY REFERENCE OF CONTENTS OF**

**REGISTRATION STATEMENTS ON FORM S-8**

Except as set forth below, the contents of the Registration Statements on Form S-8 with registration numbers listed below and, in each case, filed with the Securities and Exchange Commission (the "Commission") relating to the 2018 Plan and the 2018 ESPP, are incorporated by reference herein.

&nbsp;&nbsp;&nbsp;&nbsp;· Reg.
No. [333-285211](https://www.sec.gov/Archives/edgar/data/1730430/000110465925016951/tm256599d1_s8.htm) , filed with the Commission on February 25, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;· Reg. Nos. [333-277480](https://www.sec.gov/Archives/edgar/data/1730430/000110465924028816/tm246125d1_s8.htm) , [333-270226](https://www.sec.gov/Archives/edgar/data/1730430/000110465923027943/tm237170d1_s8.htm) , [333-262971](https://www.sec.gov/Archives/edgar/data/1730430/000110465922026626/tm226067d1_s8.htm) , [333-253514](https://www.sec.gov/Archives/edgar/data/1730430/000110465921028264/tm217773d1_s8.htm) , [333-237589](https://www.sec.gov/Archives/edgar/data/1730430/000110465920044166/tm2014936-1_s8.htm) , [333-225196](https://www.sec.gov/Archives/edgar/data/1730430/000110465918035758/a18-14278_1s8.htm) ,
each as amended by a Post-Effective Amendment No. 1, filed with the Commission on June 28, 2024.

**PART II**

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**Item 8.** **Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| <br>**Exhibit Number** | <br>**Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing<br> Date** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex3-1.htm) | [Articles of Association of Kiniksa Pharmaceuticals International, plc](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex3-1.htm) | [8-K12B](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex3-1.htm) | [001-38492](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex3-1.htm) | [6/28/2024](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex3-1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex4-1.htm) | [Specimen Share Certificate evidencing the Class A Ordinary Shares](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex4-1.htm) | [8-K12B](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex4-1.htm) | [001-38492](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex4-1.htm) | [4.1](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex4-1.htm) | [6/28/2024](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex4-1.htm) |
| [5.1](tm266974d1_ex5-1.htm) | [Opinion of Ropes & Gray LLP, counsel to the Registrant](tm266974d1_ex5-1.htm) |  |  |  | [\*](tm266974d1_ex5-1.htm) |
| [23.1](tm266974d1_ex23-1.htm) | [Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm](tm266974d1_ex23-1.htm) |  |  |  | [\*](tm266974d1_ex23-1.htm) |
| [23.2](tm266974d1_ex5-1.htm) | [Consent of Ropes & Gray LLP (included in Exhibit 5.1)](tm266974d1_ex5-1.htm) |  |  |  | [\*](tm266974d1_ex5-1.htm) |
| [24.1](#m_001) | [Power of attorney (included on signature pages below)](#m_001) |  |  |  | [\*](#m_001) |
| [99.1](https://www.sec.gov/Archives/edgar/data/1730430/000155837025009738/knsa-20250630xex10d9.htm) | [2018 Incentive Award Plan and forms of award agreements thereunder](https://www.sec.gov/Archives/edgar/data/1730430/000155837025009738/knsa-20250630xex10d9.htm) | [10-Q](https://www.sec.gov/Archives/edgar/data/1730430/000155837025009738/knsa-20250630xex10d9.htm) | [001-38492](https://www.sec.gov/Archives/edgar/data/1730430/000155837025009738/knsa-20250630xex10d9.htm) | [10.9](https://www.sec.gov/Archives/edgar/data/1730430/000155837025009738/knsa-20250630xex10d9.htm) | [7/29/2025](https://www.sec.gov/Archives/edgar/data/1730430/000155837025009738/knsa-20250630xex10d9.htm) |
| [99.2](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-5.htm) | [2018 Incentive Award Plan; Subplan for UK Employees and forms of award agreements thereunder](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-5.htm) | [8-K12B](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-5.htm) | [001-38492](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-5.htm) | [10.5](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-5.htm) | [6/28/2024](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-5.htm) |
| [99.3](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-6.htm) | [2018 Incentive Award Plan; Forms of option grant notice and option agreement for German participants, restricted share grant notice and restricted share agreement for German participants, and restricted share unit grant notice and restricted share unit agreement for German participants](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-6.htm) | [8-K12B](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-6.htm) | [001-38492](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-6.htm) | [10.6](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-6.htm) | [6/28/2024](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-6.htm) |
| [99.4](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-7.htm) | [2018 Incentive Award Plan forms of option grant notice and option agreement for Swiss participants, restricted share grant notice and restricted share agreement for Swiss participants, and restricted share unit grant notice and restricted share unit agreement for Swiss participants](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-7.htm) | [8-K12B](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-7.htm) | [001-38492](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-7.htm) | [10.7](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-7.htm) | [6/282024](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-7.htm) |
| [99.5](https://www.sec.gov/Archives/edgar/data/1730430/000155837024005774/knsa-20240331xex10d2.htm) | [Form of 2024 Performance Share Unit Grant Notice and 2024 Performance Share Unit Award Agreement](https://www.sec.gov/Archives/edgar/data/1730430/000155837024005774/knsa-20240331xex10d2.htm) | [10-Q](https://www.sec.gov/Archives/edgar/data/1730430/000155837024005774/knsa-20240331xex10d2.htm) | [001-38492](https://www.sec.gov/Archives/edgar/data/1730430/000155837024005774/knsa-20240331xex10d2.htm) | [10.2](https://www.sec.gov/Archives/edgar/data/1730430/000155837024005774/knsa-20240331xex10d2.htm) | [4/25/2024](https://www.sec.gov/Archives/edgar/data/1730430/000155837024005774/knsa-20240331xex10d2.htm) |
| [99.6](https://www.sec.gov/Archives/edgar/data/1730430/000155837025005847/knsa-20250331xex10d1.htm) | [Form of 2025 Performance Share Unit Grant Notice and 2025 Performance Share Unit Award Agreement](https://www.sec.gov/Archives/edgar/data/1730430/000155837025005847/knsa-20250331xex10d1.htm) | [10-Q](https://www.sec.gov/Archives/edgar/data/1730430/000155837025005847/knsa-20250331xex10d1.htm) | [001-38492](https://www.sec.gov/Archives/edgar/data/1730430/000155837025005847/knsa-20250331xex10d1.htm) | [10.1](https://www.sec.gov/Archives/edgar/data/1730430/000155837025005847/knsa-20250331xex10d1.htm) | [4/29/2025](https://www.sec.gov/Archives/edgar/data/1730430/000155837025005847/knsa-20250331xex10d1.htm) |
| [99.7](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-8.htm) | [2018 Employee Share Purchase Plan](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-8.htm) | [8-K12B](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-8.htm) | [001-38492](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-8.htm) | [10.8](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-8.htm) | [6/28/2024](https://www.sec.gov/Archives/edgar/data/1730430/000110465924076282/tm2417839d12_ex10-8.htm) |
| [99.8](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-1.htm) | [KPL-387 Long-Term Incentive Plan for Executive Officers](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-1.htm) | [8-K](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-1.htm) | [001-38492](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-1.htm) | [10.1](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-1.htm) | [4/23/2025](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-1.htm) |
| [99.9](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-2.htm) | [Form of Milestone 1 PSU Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-2.htm) | [8-K](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-2.htm) | [001-38492](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-2.htm) | [10.2](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-2.htm) | [4/23/2025](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-2.htm) |
| [99.10](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-3.htm) | [Form of Milestone 2 PSU Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-3.htm) | [8-K](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-3.htm) | [001-38492](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-3.htm) | [10.3](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-3.htm) | [4/23/2025](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-3.htm) |
| [99.11](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-4.htm) | [Form of Milestone 1 Option Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-4.htm) | [8-K](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-4.htm) | [001-38492](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-4.htm) | [10.4](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-4.htm) | [4/23/2025](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-4.htm) |
| [99.12](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-5.htm) | [Form of Milestone 2 Option Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-5.htm) | [8-K](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-5.htm) | [001-38492](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-5.htm) | [10.5](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-5.htm) | [4/23/2025](http://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_ex10-5.htm) |
| [107](tm266974d1_ex-filingfees.htm) | [Filing Fee Table.](tm266974d1_ex-filingfees.htm) |  |  |  | [\*](tm266974d1_ex-filingfees.htm) |

---

\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on this 24th day of February 2026.

---

| | |
|:---|:---|
| **KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC** | **KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC** |
| By: | /s/ Sanj K. Patel |
|  | Sanj K. Patel |
|  | Chief Executive Officer and Chairman of the Board |

---

**POWER OF ATTORNEY**

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sanj K. Patel and Mark Ragosa, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **SIGNATURE** | **TITLE** | **DATE** |
| /s/ Sanj K. Patel | Chief Executive Officer and Chairman of the Board of Directors | February 24, 2026 |
| Sanj K. Patel | (*principal executive officer*) |  |
| /s/ Mark Ragosa | Chief Financial Officer | February 24, 2026 |
| Mark Ragosa | (*principal financial officer*) |  |
| /s/ Michael R. Megna | Chief Accounting Officer | February 24, 2026 |
| Michael R. Megna | (*principal accounting officer*) |  |
| /s/ Felix J. Baker | Lead Independent Director | February 24, 2026 |
| Felix J. Baker |  |  |
| /s/ Stephen R. Biggar | Director | February 24, 2026 |
| Stephen R. Biggar |  |  |
| /s/ M. Cantey Boyd | Director | February 24, 2026 |
| M. Cantey Boyd |  |  |
| /s/ G. Bradley Cole | Director | February 24, 2026 |
| G. Bradley Cole |  |  |
| /s/ Richard S. Levy | Director | February 24, 2026 |
| Richard S. Levy |  |  |
| /s/ Thomas R. Malley | Director | February 24, 2026 |
| Thomas R. Malley |  |  |
| /s/ Tracey L. McCain | Director | February 24, 2026 |
| Tracey L. McCain |  |  |
| /s/ Kimberly J. Popovits | Director | February 24, 2026 |
| Kimberly J. Popovits |  |  |
| /s/ Barry D. Quart | Director | February 24, 2026 |
| Barry D. Quart |  |  |

---

**U.S. AUTHORIZED REPRESENTATIVE**

Pursuant to the requirements of the Securities Act of 1933, as amended, the duly authorized representative in the United States of the Registrant has signed this registration statement, on this 24th day of February 2026.

---

| | |
|:---|:---|
| KINIKSA PHARMACEUTICALS CORP. | KINIKSA PHARMACEUTICALS CORP. |
| By: | /s/ Sanj K. Patel |
|  | Sanj K. Patel |
|  | Chief Executive Officer |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm266974d1_ex5-1img01.jpg) | ROPES & GRAY <br> 60 LUDGATE HILL <br> LONDON EC4M 7AW <br> UNITED KINGDOM <br> WWW.ROPESGRAY.COM |

---

24 February 2026

Kiniksa Pharmaceuticals International, plc

Third Floor, 23 Old Bond Street,

London, United Kingdom, W1S 4PZ

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **Introduction**

We have acted as English law legal advisers to Kiniksa Pharmaceuticals International, plc, a public limited company incorporated under the laws of England and Wales with company number 15630565 (the "**Company**"), in connection with the registration statement on Form S-8 (the "**Registration Statement**") to be filed on or about 24 February 2026 by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "**Securities Act**"), and the rules and regulations promulgated thereunder, relating to the registration of: (i) 3,051,742 A ordinary shares of $0.000273235 each in the capital of the Company (the "**A Ordinary Shares**") issuable under the Company's 2018 Incentive Award Plan (the "**2018 Plan Shares**"); and (ii) an additional 110,000 A Ordinary Shares issuable under the Company's 2018 Employee Share Purchase Plan (together with the Company's 2018 Incentive Award Plan, the "**Kiniksa Equity Incentive Plans**") (the "**2018 ESPP Shares**" and together with the 2018 Plan Shares, the "**Shares**").

We understand that no Shares are, or are intended to be, admitted to trading on any market or exchange, or otherwise listed in, the United Kingdom.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** **Documents Examined and Searches conducted**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 For the purpose of giving this opinion, we have examined the following documents and records, and made the following searches and enquiries:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a copy of the Registration Statement to
 be filed with the Securities and Exchange Commission on 24 February 2026, as amended;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) copies of the Company's certificate
 of incorporation and articles of association, each existing as at the date of this opinion;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a
 pdf copy of each of the Kiniksa Equity Incentive Plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the
 results of our online search on 24 February 2026 at 9:53 a.m. (UK)
 of the Company's public records held by the UK Registrar of Companies (the "**Company Search** "); and

Ropes & Gray International LLP is a limited liability partnership registered in Delaware, United States of America and is a recognised body authorised and regulated by the Solicitors Regulation Authority (with registered number 521000).

![](tm266974d1_ex5-1img02.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) the
 results of our enquiry by telephone at the Companies Court in London of the Central Index
 of Winding Up Petitions on 24 February 2026 at 10:52 a.m. (UK) with
 respect to the Company (the "**Winding up Search** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 The documents, records, searches and enquiries referred to above are the only documents and records we have examined and the only searches and enquiries we have carried out for the purposes of giving this opinion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.** **Scope**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 This opinion is limited to (i) the laws of England and Wales as applied by the English courts as at the date of this letter; and (ii) those facts and circumstances which exist as at the date of this letter and we do not undertake to update or supplement this letter to reflect any facts or circumstances which may subsequently come to our attention, any changes in law or HM Revenue & Customs practice which may occur after the date of this letter, or to inform the addressees of any change in circumstances happening after the date of this letter which would alter the opinions expressed in this letter. We have not investigated, and do not express or imply any opinion in relation to, the laws of any other jurisdiction and we do not express any opinion on European Community law as it affects any jurisdiction other than England and Wales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 We expressly disclaim any responsibility to advise you of any development or circumstance of any kind, including any change of law or fact, that may occur after the date of this letter that may affect the opinion expressed herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 The opinion given in this letter is strictly limited to the matters stated in paragraph 5 and does not extend to, and is not to be read as extended by implication to, any other matters. We have not been responsible for verifying whether statements of fact (including, without limitation, foreign law), opinion or intention in the documents referred to in paragraph 2.1 above or any related documents are accurate, complete or reasonable. We express no opinion as to whether a foreign court (applying its own conflict law) will act in accordance with any agreement by the Company in connection with the issuance of the Shares as to jurisdiction and/or law. To the extent that the laws of any foreign jurisdictions may be relevant, we have made no independent investigation of such laws, and this opinion is subject to the effect of such laws. We express no opinion as to matters of fact.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 This opinion shall be governed by and construed in accordance with English law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.** **Assumptions**

In giving this opinion, we have assumed:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 the genuineness of all signatures, stamps and seals on, and the authenticity, accuracy and completeness of, all documents submitted to us (whether as originals or copies and whether in electronic form or otherwise) and that such documents remain accurate, up to date and have not been amended or any provision thereof varied or waived since the date of submission to us;

![](tm266974d1_ex5-1img02.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 that all copy documents submitted to us are complete and conform to the originals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 that on each date of the allotment and issue of the Shares (each an "**Allotment Date**") the Company has complied with all applicable laws to allot and issue the Shares and the Company has received such amounts as are necessary to fully pay the nominal value of the Shares and any applicable share premium;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 that the information revealed by the Company Search was and remains complete, accurate and up to date in all respects as at the date of this letter and will so remain as at the Allotment Dates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 that the information revealed by our Winding up Search was accurate in all respects and has not since the time of such enquiry been altered;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 that no additional matters would have been disclosed by company searches at the UK Registrar of Companies or the Companies Court being carried out since the carrying out of the searches and enquiries referred to in paragraph 2.1 above which would affect the opinion stated below and that the particulars disclosed by our searches and enquiries are true, accurate, complete and up to date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 that no step has been taken to wind up, strike off or dissolve the Company or appoint an administrator or receiver or nominee or supervisor in respect of a company voluntary arrangement or similar official in respect of the Company or any of its assets or revenues or to obtain a moratorium which has not been revealed by our searches referred to above;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8 that the term "non-assessable", which has no recognised meaning in English law, for the purposes of this letter means that, under the Companies Act 2006 (as amended), the articles of association of the Company and any resolution taken under the articles of association of the Company approving the issuance of the Shares, no holder of such Shares is liable, solely because of such holder's status as a holder of such Shares, for additional assessments or calls for further funds by the Company or any other person; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9 that the directors as at the time of the Allotment Dates will be duly authorised pursuant to the articles of association of the Company as in force at the time of the Allotment Dates, the Companies Act 2006 and any relevant authority given by the members of the Company in a general meeting to allot and issue Shares on a non pre-emptive basis and that as at each date on which the Company allots and issues Shares, the board of directors of the Company, a duly authorised committee of the board of directors or a duly authorised director will have validly resolved to allot and issue the relevant Shares.

![](tm266974d1_ex5-1img02.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **Opinion**

Based upon the foregoing and subject to any matters not disclosed to us and to the assumptions and qualifications set out in this letter, we are of the opinion that the Shares will be duly authorised, validly issued, fully paid and non-assessable when: (i) the Registration Statement becomes effective under the Securities Act; (ii) the Shares are paid for in accordance with the rules of the applicable Kiniksa Equity Incentive Plan and (iii) valid entries in the books and registers of the Company have been made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.** **Qualifications**

The opinion given in this letter is subject to the qualifications and reservations set out below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 The Company Search is not capable of revealing conclusively whether or not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a winding-up order has been made or a
 resolution passed for the winding up of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) an administration order has been made;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a receiver, administrative receiver, administrator
 or liquidator has been appointed; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) a court order has been made under the
 Cross Border Insolvency Regulations 2006,

since notice of these matters may not be filed with the Registrar of Companies immediately and, when filed, there may be a delay in the relevant notice appearing on the file of the company concerned.

In addition, the Company Search is not capable of revealing, prior to the making of the relevant order or the appointment of an administrator otherwise taking effect, whether or not a winding-up petition or an application for an administration order has been presented, or whether or not any documents for the appointment of, or notice of intention to appoint, an administrator under paragraphs 14 or 22 of Schedule B1 to the Insolvency Act 1986 has been filed with the court.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 The Winding up Search relates only to the presentation of (i) a petition for the making of a winding-up order or the making of a winding-up order by a court, (ii) an application to the High Court of Justice in London for the making of an administration order and the making by such court of an administration order, and (iii) a notice of intention to appoint an administrator or a notice of appointment of an administrator filed at the High Court of Justice in London. It is not capable of revealing conclusively whether or not such a winding-up petition, application for an administration order, notice of intention or notice of appointment has been presented or winding-up or administration order granted, because:

![](tm266974d1_ex5-1img02.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) details of a winding-up petition or application
 for an administration order may not have been entered on the records of the Central Index
 of Winding Up Petitions immediately;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) in the case of an application for the
 making of an administration order and such order and the presentation of a notice of intention
 to appoint or notice of appointment, if such application is made to, order made by or notice
 filed with, a court other than the High Court of Justice in London, no record of such application,
 order or notice will be kept by the Central Index of Winding Up Petitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a winding-up order or administration order
 may be made before the relevant petition or application has been entered on the records of
 the Central Index of Winding Up Petitions, and the making of such order may not have been
 entered on the records immediately;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) details of a notice of intention to appoint
 an administrator or a notice of appointment of an administrator under paragraphs 14 and 22
 of Schedule B1 of the Insolvency Act 1986 may not be entered on the records immediately (or,
 in the case of a notice of intention to appoint, at all); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) with regard to winding-up petitions, the
 Central Index of Winding Up Petitions may not have records of winding-up petitions issued
 prior to 1994.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 We express no opinion as to matters of United Kingdom taxation or any liability to tax which may arise or be incurred as a result of or in connection with the Shares or the Kiniksa Equity Incentive Plans (or the transactions contemplated thereby), or as to tax matters generally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 The opinion set out in paragraph 5 relates only to Shares contemplated by the Registration Statement that are new ordinary shares issued by the Company from time to time pursuant to the Kiniksa Equity Incentive Plans following the date of the Registration Statement. We express no opinion in respect of any other securities of the Company.

**7.** **Consent to Filing**

We hereby consent to your filing this opinion as an exhibit to the Registration Statement and to the use of our name therein and in the related prospectus under the caption "Legal matters." In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Ropes & Gray International LLP |
| **Ropes & Gray International LLP** |

---

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Kiniksa Pharmaceuticals International, plc of our report dated February 24, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Kiniksa Pharmaceuticals International, plc's Annual Report on Form 10-K for the year ended December 31, 2025.

---

| |
|:---|
| /s/ PricewaterhouseCoopers LLP |
| Boston, Massachusetts |
| February 24, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Kiniksa Pharmaceuticals International, plc**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Class A ordinary shares, nominal value $0.000273235 per share | 457(a) | 3051742 | $47.30 | $144347396.60 | 0.0001381 | $19934.38 |
| 2 | Equity | Class A ordinary shares, nominal value $0.000273235 per share | 457(a) | 110000 | $47.30 | $5203000.00 | 0.0001381 | $718.53 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $149550396.60  |  | $20652.91  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $20652.91  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> 1(a) In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued under the Kiniksa Pharmaceuticals International, plc 2018 Incentive Award Plan (the "2018 Plan") and the Kiniksa Pharmaceuticals International, plc 2018 Employee Share Purchase Plan (the "2018 ESPP") to prevent dilution resulting from stock splits, stock dividends or similar transactions. In addition, pursuant to Rule 416(c) under the Securities Act of 1933, this registration statement also covers an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. 1(b) Consists of 3,051,742 Class A ordinary shares, nominal value $0.000273235 per share of the Registrant ("Class A ordinary shares") that may become issuable under the 2018 Plan pursuant to its terms. 1(c) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, and based upon the average of the high and low prices of the Class A ordinary shares as reported on the Nasdaq Global Select Market on February 20, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> 2(a) In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued under the Kiniksa Pharmaceuticals International, plc 2018 Incentive Award Plan (the "2018 Plan") and the Kiniksa Pharmaceuticals International, plc 2018 Employee Share Purchase Plan (the "2018 ESPP") to prevent dilution resulting from stock splits, stock dividends or similar transactions. In addition, pursuant to Rule 416(c) under the Securities Act of 1933, this registration statement also covers an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. 2(b) Consists of 110,000 Class A ordinary shares that may become issuable under the 2018 ESPP pursuant to its terms. 2(c) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act, and based upon the average of the high and low prices of the Class A ordinary shares as reported on the Nasdaq Global Select Market on February 20, 2026.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---